These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26019689)

  • 1. The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims.
    Garris C; Shah M; Farrelly E
    Cost Eff Resour Alloc; 2015; 13():9. PubMed ID: 26019689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
    Wu SS; Perry A; Tkacz J; Bryant G
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
    [No Abstract]   [Full Text] [Related]  

  • 5. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States.
    Murimi-Worstell IB; Lin DH; Kan H; Tierce J; Wang X; Nab H; Desta B; Alexander GC; Hammond ER
    J Rheumatol; 2021 Mar; 48(3):385-393. PubMed ID: 32611669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

  • 7. Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis.
    Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM; Von Feldt J
    Cureus; 2023 Apr; 15(4):e37839. PubMed ID: 37214060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.
    Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T
    Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonoperative care to manage sacroiliac joint disruption and degenerative sacroiliitis: high costs and medical resource utilization in the United States Medicare population.
    Ackerman SJ; Polly DW; Knight T; Holt T; Cummings J
    J Neurosurg Spine; 2014 Apr; 20(4):354-63. PubMed ID: 24527824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study.
    He X; Zhu X; Tang Z; Gairy K; Juliao P; Wu Z; Han S
    Value Health Reg Issues; 2024 Sep; 43():101001. PubMed ID: 38850589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
    Bell CF; Ajmera MR; Meyers J
    Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
    He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
    Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population.
    Li T; Carls GS; Panopalis P; Wang S; Gibson TB; Goetzel RZ
    Arthritis Rheum; 2009 Jun; 61(6):755-63. PubMed ID: 19479688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender Disparities in Hospitalization Outcomes and Healthcare Utilization Among Patients with Systemic Lupus Erythematosus in the United States.
    Uwumiro F; Okpujie VO; Osemwota O; Okafor NE; Otu MI; Borowa A; Ezerioha P; Tejere E; Alemenzohu H; Bojerenu MM
    Cureus; 2023 Jul; 15(7):e41254. PubMed ID: 37529818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
    Jiang M; Near AM; Desta B; Wang X; Hammond ER
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.
    O'Malley T; Xie F; Su Y; Clinton C; Zack DJ; Haechung C; Grabner M; Curtis JR
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1021-1032. PubMed ID: 35775579
    [No Abstract]   [Full Text] [Related]  

  • 17. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
    Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
    J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany.
    Schultze M; Garal-Pantaler E; Pignot M; Levy RA; Carnarius H; Schneider M; Gairy K
    BMC Rheumatol; 2024 May; 8(1):18. PubMed ID: 38755673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    J Med Econ; 2020 Jul; 23(7):786-799. PubMed ID: 32149541
    [No Abstract]   [Full Text] [Related]  

  • 20. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid.
    Kan HJ; Song X; Johnson BH; Bechtel B; O'Sullivan D; Molta CT
    Biomed Res Int; 2013; 2013():808391. PubMed ID: 23484162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.